Allakos Inc. (ALLK)
May 15, 2025 - ALLK was delisted (reason: acquired by Concentra Biosciences)
0.3291
-0.0002 (-0.06%)
Inactive · Last trade price on May 14, 2025

Allakos Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
41.138.8245.1557.3575.1551.52
Research & Development
58.6579.94150.91265.08196.33105.53
Operating Expenses
99.75118.76196.06322.43271.48157.06
Operating Income
-99.75-118.76-196.06-322.43-271.48-157.06
Interest & Investment Income
5.26.4510.353.670.384.31
Other Non Operating Income (Expenses)
-0.19-0.040.01-1.17-0.59-0.74
EBT Excluding Unusual Items
-94.74-112.35-185.7-319.92-271.69-153.48
Gain (Loss) on Sale of Assets
---0-0.03-0.05-
Asset Writedown
--27.35----
Other Unusual Items
23.8823.88--1.87-
Pretax Income
-70.85-115.82-185.7-319.95-269.86-153.48
Net Income
-70.85-115.82-185.7-319.95-269.86-153.48
Net Income to Common
-70.85-115.82-185.7-319.95-269.86-153.48
Shares Outstanding (Basic)
898987635449
Shares Outstanding (Diluted)
898987635449
Shares Change (YoY)
2.18%2.30%37.16%17.56%8.77%9.52%
EPS (Basic)
-0.79-1.30-2.14-5.06-5.01-3.10
EPS (Diluted)
-0.79-1.30-2.14-5.06-5.01-3.10
Free Cash Flow
-89.69--117.07-288.3-241.07-114.55
Free Cash Flow Per Share
-1.00--1.35-4.56-4.48-2.31
EBITDA
-84.93-115-189.92-315.36-269.17-155.51
D&A For EBITDA
14.823.766.147.072.311.55
EBIT
-99.75-118.76-196.06-322.43-271.48-157.06
Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q